Pluri price to sales ratio PLUR

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 12.0×
10-year median: 44.8×
Against its 10-year history: 1st; percentile: 0 is its lowest day, 100 its highest
10-year range: 11.3× to 194×
Peer median: 1.1×

Pluri's price to sales ratio is 12.0× as of Oct 23, 2026.

That is below its ten-year median of 44.8×, lower than on 99% of days in the last ten years.

Over that time it ranged from 11.3× in Oct 2026 to 194× in Jun 2023.

The median for 7 healthcare stocks of a similar size is 1.1×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	12.0×	11.3×	33.7×
2025	21.7×	20.1×	59.3×
2024	42.3×	42.3×	131×
2023	94.7×	69.2×	194×
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	31.9×	31.3×	44.4×
2016	40.7×	21.3×	184×

Against its peers

Companies in Healthcare nearest Pluri's size, closest first, today.

Company	Price to sales ratio
PLURPluri	12.0×
NEPHNephros	1.9×
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	0.9×
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
ICCCImmucell	3.0×
KEQUKewaunee Scientific	0.3×
Peer median	1.1×

Where Pluri ranks

#43of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Pluri

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.